Expanding its offerings in the development and manufacturing of biologic products
Catalent Pharma Solutions will relocate to a new facility in Madison, Wisconsin, US late 2012.
The plant will quadruple the firm’s current capacity in Middleton, Wisconsin, allowing it to expand its offerings in the development and manufacturing of biologic products.
The expansion will also enhance the efficiency and output of Catalent’s GPEx cell line engineering technology and process development capabilities, as well as other mammalian cell lines.
‘Plans for the biologics facility are designed to meet our customers’ needs through improved delivery of integrated services in the areas of biologic development and manufacturing,’ said Kent Payne, vice president and general manager of Catalent’s Biologics business.
‘This is the first step in a series of strategic development initiatives designed to enhance our offerings in this rapidly expanding market.’
Supported by numerous process upgrades and increased capabilities in process development, the new facility will include three current Good Manufacturing Practice (cGMP) compliant production suites that will increase Phase I and II production capacity up to 1,000L bioreactors.
Catalent will also move from stainless steel to single-use bioreactors, further increasing capacity by extending the number of batches produced per suite and allowing greater flexibility in the scale of cGMP manufacturing capacity.